Adipotide [Nasal Spray]

Description

What is Adipotide (FTPP) Nasal Spray?

Adipotide (FTPP; Fat-Targeted Proapoptotic Peptide; prohibitin-targeting peptide 1; TP01) is a synthetic chimeric peptidomimetic with the sequence CKGGRAKDC-GG-D(KLAKLAK)2. The compound was developed by Mikhail Kolonin, Pradip Saha, Lawrence Chan, Renata Pasqualini, and Wadih Arap at the University of Texas M.D. Anderson Cancer Center. It consists of two functionally distinct domains connected by a glycine-glycine (GG) linker: a white adipose tissue-homing domain (CKGGRAKDC), isolated by in vivo phage display screening as a sequence that homes to the vasculature of white adipose tissue and binds to the membrane protein prohibitin; and a proapoptotic effector domain (D(KLAKLAK)2), a D-amino acid peptide that disrupts mitochondrial membrane integrity and initiates apoptosis upon cellular internalization. The compound acts as a ligand-directed peptidomimetic: the homing domain targets the endothelial cells of white adipose tissue vasculature, and the proapoptotic domain drives those cells toward programmed cell death, severing the blood supply to fat depots. Clinical development was discontinued as of 2019. Adipotide has not been approved as a registered pharmaceutical in any country and has not been approved by the Food and Drug Administration for any indication.

The compound has been investigated in diet-induced and spontaneously obese mouse model systems, rhesus macaque, baboon, and cynomolgus macaque primate preparations, for its effects on white adipose tissue ablation, body weight reduction, body fat distribution, and insulin resistance. Research has characterized prohibition as a vascular marker expressed on white adipose tissue blood vessels in both rodent and human specimens. The primate study published in Science Translational Medicine in 2011 represents the only published non-human primate data and identified dose-dependent reversible renal proximal tubule changes as the primary toxicity signal. No completed human clinical trial data have been published as of June 2026.

The nasal spray formulation is investigated as a delivery route in preclinical research contexts, based on evidence of olfactory bulb-mediated CNS transport for peptide compounds administered intranasally in rodent models. Intranasal delivery has been studied for its potential to bypass hepatic first-pass metabolism and enhance CNS bioavailability relative to systemic routes in preclinical pharmacokinetic models. The nasal mucosa’s proximity to the central nervous system via the olfactory nerve makes it a research-relevant delivery route for research compounds.

DISCLAIMER: Adipotide (FTPP) Nasal Spray, as supplied by RCDbio, is not a dietary supplement, is not approved by the Food and Drug Administration for human or veterinary use, and is not intended for human consumption or therapeutic self-administration. All RCDbio research compounds are supplied strictly for laboratory and research purposes only.

Chemical Properties of Adipotide (FTPP)

How Does Adipotide (FTPP) Work?

Adipotide operates via a two-domain ligand-directed mechanism. The CKGGRAKDC homing domain targets and binds prohibitin, a multifunctional membrane protein expressed on the surface of endothelial cells in white adipose tissue vasculature. Upon binding, the compound is internalized. Once intracellular, the D(KLAKLAK)2 proapoptotic domain disrupts mitochondrial membrane integrity, triggering programmed cell death in the targeted endothelial cells. The resulting vascular ablation severs the blood supply to fat depots, inducing adipocyte apoptosis through ischemia. No single confirmed receptor mediates the full chimeric activity; prohibitin/ANXA2 binding drives tissue targeting, while the proapoptotic domain acts on the mitochondria. The following mechanistic observations are from preclinical and in vitro data only.

Prohibitin as a Vascular Marker of White Adipose Tissue

In vivo phage display screening in obese C57BL/6 mice identified the peptide motif CKGGRAKDC as a sequence that homes selectively to white fat vasculature. The CKGGRAKDC peptide associates with prohibitin, establishing prohibitin as a vascular marker of white adipose tissue. Prohibitin expression was confirmed on blood vessels of human white fat specimens as well as in rodent preparations, supporting the translational research relevance of the targeting mechanism [Kolonin et al., 2004; PMID 15133506]. The intact chimeric adipotide compound targeted this prohibitin-expressing vasculature and caused ablation of white fat and normalization of metabolism in obese mouse preparations.

Proapoptotic Domain and Mitochondrial Disruption

The D(KLAKLAK)2 domain is a D-amino acid repeat sequence that disrupts mitochondrial membranes upon internalization into eukaryotic cells. D-amino acid configuration confers resistance to proteolytic degradation by aminopeptidases that preferentially cleave L-amino acid substrates. Once delivered intracellularly via the prohibitin/ANXA2-mediated homing mechanism, this domain initiates apoptosis in targeted endothelial cells. The D-amino acid proapoptotic domain’s mitochondria-disrupting activity is not inherently cell-type-selective in isolation; selectivity depends on the tissue-homing function of the CKGGRAKDC targeting domain.

Vascular Ablation, Adipose Tissue Resorption, and Metabolic Normalization

Targeting the proapoptotic domain to prohibitin in white adipose vasculature caused ablation of white fat in obese mouse preparations. Resorption of established white adipose tissue and normalization of metabolism resulted in rapid obesity reversal in these preparations without detectable adverse effects at the doses studied [Kolonin et al., 2004; PMID 15133506]. In obese Old World primate preparations, adipotide treatment induced targeted apoptosis within white adipose tissue blood vessels, resulting in rapid weight loss and improved insulin resistance. MRI and DEXA imaging confirmed marked reduction in white adipose tissue in these primate preparations [Barnhart et al., 2011; PMID 22072637].

Renal Proximal Tubule Toxicity Signal

At experimentally determined optimal doses in primate preparations, monkeys from three species displayed predictable and reversible changes in renal proximal tubule function. The primary side effect was relatively mild and reversible renal tubular injury, characterized by altered tubular function markers including decreased serum phosphorus and potassium, glucosuria, and proteinuria [Barnhart et al., 2011; PMID 22072637]. Renal toxicity is the primary safety concern because the CKGGRAKDC homing domain is cleared renally after dissociation from adipose binding sites; at sufficient non-targeted concentrations, the D(KLAKLAK)2 domain’s mitochondria-disrupting activity may affect renal tubular cells. No human renal toxicity or pharmacokinetic data has been published.

Intranasal Delivery & Pharmacokinetics

Olfactory Bulb-Mediated CNS Transport

When administered intranasally in preclinical rodent model systems, peptide compounds can access the central nervous system through the olfactory nerve (cranial nerve I) pathway. Compounds deposited on the olfactory mucosa are transported along olfactory axons through the cribriform plate to the olfactory bulb, from which access to deeper CNS structures has been characterized in rodent preparations. The olfactory and trigeminal nerve pathways for nose-to-brain peptide transport have been investigated in preclinical studies of peptide and protein delivery [Wong et al., 2024; PMID 38441832]. No compound-specific olfactory transport data for adipotide has been published. Adipotide’s primary research context is peripheral vascular targeting of white adipose tissue endothelium; CNS-directed research applications are not the primary rationale for the intranasal route.

Hepatic First-Pass Metabolism Bypass

The intranasal route avoids portal circulation and hepatic first-pass metabolic processing. Adipotide’s D(KLAKLAK)2 proapoptotic domain uses D-amino acid configuration, which confers resistance to aminopeptidase-mediated degradation in biological fluids. The CKGGRAKDC homing domain is composed of L-amino acids and is susceptible to proteolytic degradation in the GI environment. Intranasal delivery bypasses GI proteolytic exposure. These observations do not constitute evidence of intranasal efficacy in human subjects.

Nasal Mucosal Absorption

Adipotide has an approximate molar mass of ~2555 g/mol (~2.55 kDa based on PubChem CID 163360068). This molecular weight falls within the 1-5 kDa bracket, indicating paracellular and endocytic uptake mechanisms are likely predominant absorption pathways at the nasal mucosa. The chimeric domain architecture represents an unusual structural profile for intranasal peptide absorption; no published mucosal permeability data exist for this compound class. Specific nasal mucosal permeability coefficients for adipotide have not been published.

Compound-Specific Pharmacokinetics

No formal intranasal pharmacokinetic data for adipotide has been published in the peer-reviewed literature as of June 2026. All published preclinical research uses subcutaneous injection at doses of 0.43 mg/kg in primate preparations. No human pharmacokinetic data has been published for any route of administration. Researchers should account for the complete absence of published intranasal-specific pharmacokinetic parameters when designing laboratory protocols.

Key Research Findings

Prohibitin as a Vascular Marker of White Adipose Tissue and Obesity Reversal in Obese Mice (C57BL/6 Mouse Preparation): In vivo phage display identified CKGGRAKDC as a peptide homing to white fat vasculature; CKGGRAKDC was shown to associate with prohibitin, establishing prohibitin as a white adipose tissue vascular marker; targeting a proapoptotic peptide to prohibitin in adipose vasculature caused white fat ablation, metabolic normalization, and rapid obesity reversal in obese C57BL/6 mouse preparations without detectable adverse effects [Kolonin et al., 2004; PMID 15133506]

Weight Loss, Insulin Resistance Improvement, and Renal Proximal Tubule Toxicity Signal in Obese Old World Primate Preparations: Adipotide (CKGGRAKDC-GG-D(KLAKLAK)2) in obese rhesus macaques, baboons, and cynomolgus macaques induced targeted apoptosis in white adipose tissue blood vessels; MRI/DEXA-confirmed white adipose tissue reduction, body weight loss of approximately 10-15%, and improved insulin resistance were observed; dose-dependent reversible changes in renal proximal tubule function were identified as the primary toxicity signal across three primate species [Barnhart et al., 2011; PMID 22072637]

All findings listed above are from preclinical in vivo mouse model preparations and non-human primate studies using subcutaneous injection. These observations do not constitute evidence of efficacy or safety for the adipotide nasal spray formulation in any organism. The renal proximal tubule toxicity signal identified in the primate study represents a documented safety finding that has not been fully characterized under chronic dosing or in humans. No human clinical data has been established for research-grade adipotide administered via any route.

What are the Potential Research Applications?

In controlled laboratory environments, adipotide nasal spray has been investigated for the following research applications. These are observed in preclinical and in vitro contexts only and do not constitute claims of efficacy or safety in any organism.

Prohibitin Biology and Vascular Targeting Research

Adipotide is the primary research tool for studying prohibitin as a vascular marker of white adipose tissue in cell and tissue preparations. Research applications include prohibitin receptor binding characterization in adipose endothelial cell preparations, comparative vascular marker expression studies across fat depot types, and prohibitin/ANXA2 co-localization studies in white versus brown adipose tissue preparations.

Adipose Tissue Vascular Ablation Research

Adipotide provides a unique model for studying targeted vascular ablation of adipose tissue in rodent model systems. Research applications include adipose tissue vascular density and remodeling studies, investigation of apoptotic signaling cascades following targeted endothelial cell death, and characterization of fat depot reduction and redistribution in diet-induced obese rodent preparations.

Proapoptotic Peptide Delivery and Targeting Research

Adipotide’s chimeric architecture provides a model compound for studying ligand-directed proapoptotic peptide delivery. Research applications include comparative internalization studies of the intact chimeric compound versus isolated domains, investigation of D-amino acid domain stability in biological matrices, and structure-activity relationship studies of alternative homing domain sequences.

Obesity and Insulin Resistance: Metabolic Research

The primary evidence base supports adipotide’s use as a tool compound in preclinical obesity model systems investigating vascular mechanisms of adipose tissue regulation. Research applications include insulin sensitivity and glucose metabolism studies following adipose vascular reduction, comparative body composition analyses in diet-induced obese rodent preparations, and metabolic normalization pathway characterization.

What are the Potential Side Effects?

Researchers in preclinical and in vitro settings have noted the following observations. Long-term safety and toxicity profiles remain incompletely characterized for the research-grade nasal spray formulation.

• Renal proximal tubule toxicity – primary documented concern (primate study): Dose-dependent reversible changes in renal proximal tubule function were observed across three primate species in the 2011 Science Translational Medicine study; findings included altered tubular function markers, glucosuria, and proteinuria; described as reversible upon cessation in the 28-day study; reversibility in a 28-day primate study does not characterize the full renal safety profile under chronic dosing, at higher doses, or in humans [Barnhart et al., 2011; PMID 22072637]
• Off-target proapoptotic domain activity (class context): The D(KLAKLAK)2 domain’s mitochondria-disrupting activity is not inherently tissue-selective in isolation; selectivity depends on the CKGGRAKDC homing function; inadvertent intranasal self-exposure or loss of homing specificity at higher concentrations carries a theoretical risk of off-target mitochondrial disruption in non-adipose tissues, including nasal mucosa cells
• Immunogenicity (class context): Chimeric peptidomimetics with D-amino acid domains may elicit immunogenic responses upon repeated exposure; no formal immunogenicity assessment has been published for adipotide in any model system
• Absence of intranasal-specific safety data: No safety or tolerability data specific to the intranasal route of administration for adipotide has been published in the peer-reviewed literature as of June 2026
• No completed human clinical trials: No human Phase 1 safety or efficacy trials for adipotide have been completed or published as of June 2026; clinical development was discontinued as of 2019

No human safety or tolerability data has been established for adipotide nasal spray via any route. These observations are derived from experimental systems and should not be extrapolated to human or animal outcomes.

Risk & Handling

Handling Precautions

Standard laboratory PPE is required: nitrile gloves, a laboratory coat, and eye protection. The following nasal spray-specific precautions apply

1. Do not direct the nasal spray actuator toward the face, eyes, or mucous membranes during handling, testing, or transfer. The D(KLAKLAK)2 proapoptotic domain may produce cytotoxic effects via inadvertent intranasal self-exposure, particularly on nasal mucosal epithelial cells.
2. Handle the nasal spray solution in a clean laboratory environment. For aliquoting or analytical sampling, use a laminar flow cabinet.
3. The nasal spray solution is an aqueous formulation susceptible to microbial contamination if compromised. Handle under aseptic conditions. Discard if the solution appears cloudy, discolored, or shows particulate matter.
4. Avoid aerosol generation during any manipulation of the nasal spray solution.

Exposure Risks

Risk Tier: MODERATE

Adipotide carries a documented renal proximal tubule toxicity signal from the 2011 primate study, representing the most specific safety concern in the RCDbio nasal spray research range. The D(KLAKLAK)2 proapoptotic domain disrupts mitochondrial membrane integrity and is potentially cytotoxic to non-targeted cells at sufficient exposure concentrations. Inadvertent intranasal self-exposure carries a risk of direct proapoptotic activity on nasal mucosal epithelial cells. Researchers should treat this compound with precautions appropriate to a potent proapoptotic peptidomimetic with documented dose-dependent organ toxicity in primate model systems. No human safety or tolerability data has been established for adipotide nasal spray via any route.

Storage

In-use nasal spray: Store at 2-8°C. Use within 28 days of first actuation. Protect from light. Keep upright

DO NOT FREEZE the ready-to-use nasal spray formulation. Freezing alters pH, buffer stability, excipient integrity, and spray actuation properties.

Lyophilized bulk stock (if applicable): Store at -20°C in sealed, desiccated, light-protected containers. Avoid repeated freeze-thaw cycles.

Discard any solution that appears cloudy, discolored, or shows visible particulate matter.

FAQs

Q: How does intranasal administration facilitate delivery of adipotide in preclinical research models?

A: Intranasal application bypasses hepatic first-pass metabolism and the GI proteolytic environment, which is relevant given adipotide’s partially protease-susceptible L-amino acid homing domain. The olfactory and trigeminal nerve pathways for peptide transport have been characterized for structurally related peptide compounds in rodent models [Wong et al., 2024; PMID 38441832]. Adipotide’s primary research target is peripheral white adipose tissue vasculature, accessible via systemic absorption following intranasal delivery. No compound-specific intranasal olfactory transport data exist for adipotide. No human delivery data has been established for research-grade adipotide via any route.

Q: What is the recommended storage and in-use shelf life for adipotide nasal spray?

A: Sealed product should be stored at 2-8°C, protected from light. Once first actuated, in-use shelf life is 28 days at 2-8°C. DO NOT FREEZE the ready-to-use solution. The chimeric domain structure may be susceptible to conformational disruption under repeated freeze-thaw conditions. Lyophilized bulk stock should be stored at -20°C in sealed, desiccated, light-protected conditions. Discard if the solution shows cloudiness, discoloration, or particulate matter.

Q: Is the adipotide nasal spray formulation suitable for cell culture or in vitro assay systems?

A: The formulation is prepared in isotonic saline (0.9% NaCl, pH 6.0-7.0) without preservatives. Researchers should note that the D(KLAKLAK)2 proapoptotic domain confers cytotoxic activity against cells expressing prohibitin or ANXA2 at sufficient concentrations; vehicle validation in non-targeted cell types is required before use in assay systems. Dilution into culture medium before application is recommended. Researchers are responsible for confirming compatibility with their assay system.

Q: What is the mechanism of adipotide’s selectivity for white adipose tissue?

A: Selectivity is driven by the CKGGRAKDC homing domain, which binds prohibitin and ANXA2 expressed on endothelial cells in white adipose tissue vasculature. Prohibitin was established as a vascular marker of white adipose tissue through phage display studies [Kolonin et al., 2004; PMID 15133506]. The D(KLAKLAK)2 proapoptotic domain is non-selective in isolation; selectivity depends on the homing domain’s binding specificity.

Q: What is the renal toxicity finding from the 2011 primate study, and how should it inform research protocol design?

A: The 2011 Science Translational Medicine study identified dose-dependent reversible changes in renal proximal tubule function as the primary toxicity signal in three primate species [Barnhart et al., 2011; PMID 22072637]. Findings included altered tubular function markers, glucosuria, and proteinuria. The kidney is the primary concern because the CKGGRAKDC homing domain is cleared renally after dissociation from adipose binding sites. Researchers using adipotide in in vivo rodent model systems should incorporate renal function endpoint monitoring.

Q: What is the WADA status of adipotide?

A: Adipotide is not explicitly named on the 2026 WADA Prohibited List. As an unapproved pharmacological substance, it may fall under the S0 catchall category. Researchers should verify the current status at GlobalDRO.com. RCDbio products are supplied for laboratory research purposes only.

Q: What is the FDA regulatory status of adipotide?

A: Adipotide is not FDA-approved for any indication and has no drug application on file. Clinical development was discontinued as of 2019. It is not a compoundable bulk drug substance under 503A or 503B. The research-grade nasal spray is for laboratory research use only.

Related Research Compounds

Researchers investigating adipotide nasal spray may also be interested in the following compounds currently available for laboratory research at RCDbio:

Liraglutide (GLP-1) Nasal Spray – A GLP-1 receptor agonist investigated in preclinical preparations for insulin resistance improvement and metabolic pathway modulation via GLP-1R/cAMP signaling in adipose-relevant research contexts.

HGH Fragment 176-191 Nasal Spray – A synthetic C-terminal growth hormone peptide investigated in preclinical preparations for hGH receptor-independent lipolysis and lipid metabolism signaling in adipocyte model systems.

BPC-157 Nasal Spray– A stable gastric pentadecapeptide investigated in preclinical rodent preparations for cytoprotection, angiogenesis, and vascular recruitment signaling.

All products listed are for laboratory and research purposes only.

References

1. Kolonin, M.G., Saha, P.K., Chan, L., Pasqualini, R., & Arap, W. (2004). Reversal of obesity by targeted ablation of adipose tissue. Nature Medicine, 10(6), 625-632.

   https://pubmed.ncbi.nlm.nih.gov/15133506/

2. Barnhart, K.F., Christianson, D.R., Hanley, P.W., Driessen, W.H.P., Bernacky, B.J., Baze, W.B., Wen, S., Tian, M., Ma, J., Kolonin, M.G., Saha, P.K., Do, K., Hulvat, J.F., Gelovani, J.G., Chan, L., Arap, W., & Pasqualini, R. (2011). A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Science Translational Medicine, 3(108), 108ra112.

   https://pubmed.ncbi.nlm.nih.gov/22072637/

3. Wong, C.Y.J., Baldelli, A., Hoyos, C.M., et al. (2024). Insulin delivery to the brain via the nasal route: unraveling the potential for Alzheimer’s Disease therapy. Drug Delivery and Translational Research, 14(7), 1776-1793.

   https://pubmed.ncbi.nlm.nih.gov/38441832/

Research Transparency Note: No peer-reviewed publications specific to intranasal delivery of adipotide are available as of June 2026. References 1 and 2 describe subcutaneous administration in mouse and non-human primate model systems. The olfactory transport pathway evidence in Reference 3 is class-level and applies to structurally related peptide compounds in rodent models. The published evidence base for adipotide is limited; clinical development was discontinued as of 2019 and no human clinical trial data has been published.

Disclaimer

Adipotide (FTPP) Nasal Spray is exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, prevent, treat, or cure any disease or medical condition.

The Food and Drug Administration has not evaluated the statements on our website. This product is not approved for human or veterinary use. Researchers must comply with all applicable local, state, and federal laws and regulations governing the purchase and use of research compounds. By purchasing, you agree to our Terms and Conditions. RCDbio reserves the right to refuse sales to unauthorized individuals.

ATTENTION: All RCDbio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not intended for human consumption, veterinary use, or any other non-research application. For queries, complaints, or support, contact support@rcdbio.co